Clinical Trial Update: YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating YTS109 in pediatric relapsed/refractory autoimmune diseases, including SLE and diffuse systemic sclerosis, is not yet recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anca-associated Vasculitis
• Antiphospholipid Syndrome
• Diffuse Systemic Sclerosis
• Idiopathic Inflammatory Myopathies
• Sjögren Syndrome
• Systemic Lupus Erythematosus

Drugs mentioned

• YTS109

Snippet

Sponsor: Children's Hospital of Fudan University | Conditions: Systemic Lupus Erythematosus (SLE), Diffuse Systemic Sclerosis | Phase 1 | Status: NOT_YET_RECRUITING